Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma.

ABSTRACT:

Significance

Patients aged ≥50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk-benefit evaluation is essential to guide optimal treatment decisions.

SUBMITTER: Liebers N 

PROVIDER: S-EPMC12050943 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature